Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.216 EUR | -1.82% | -.--% | -82.78% |
May. 28 | Mithra Delays AGM Amid Monetization Process | MT |
Apr. 29 | Mithra Pharmaceuticals to Postpone the Publication of Its Annual Report 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Most analysts recommend that the stock should be sold or reduced.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-82.78% | 16.21M | C+ | ||
-1.64% | 90.28B | A- | ||
-1.97% | 39.5B | A- | ||
-15.47% | 31.71B | B- | ||
+61.28% | 26.41B | A | ||
-22.81% | 14.34B | C | ||
-8.82% | 12.89B | B- | ||
-11.77% | 11.8B | D+ | ||
-45.97% | 10.95B | B | ||
+3.30% | 8.85B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- MITRA Stock
- Ratings Mithra Pharmaceuticals S.A.